Ophthalmic composition
AssigneeMedicure Technologies Ltd.
InventorsEyal Zolotariov, Zvi Zolotariov
Life of this patent
Estimating the term…
Abstract
A topical ophthalmic composition for treatment of dry eye is disclosed. In preferred embodiments, the composition comprises as active ingredients hyaluronic acid or a pharmaceutically acceptable salt thereof and polyvinylpyrrolidine. In other embodiments of the invention, the composition additionally comprises polyvinyl alcohol. Methods of preparation of the composition are disclosed, as well as methods for use of the composition in the treatment of dry eye.
Claims21
1-84. (canceled)
An ophthalmic composition, consisting of:
- an aqueous solution of hyaluronic acid (HA) or a pharmaceutically acceptable salt thereof;
- polyvinyl pyrrolidone (PVP);
- and,
- optionally, at least one component selected from the group consisting of inorganic salts and buffers.
The ophthalmic composition according to claim 84, wherein said buffer is a borate-boric acid buffer comprising boric acid and sodium tetraborate decahydrate in substantially equal concentrations (w/v).
A method of producing an ophthalmic composition, wherein said method comprises:
- preparing an aqueous solution comprising HA or a pharmaceutically acceptable salt thereof and PVP;
- optionally, adding at least one substance selected from the group consisting of inorganic salts and buffers;
- optionally, adding sufficient acid or base to adjust the pH to a predetermined pH;
- optionally:
- adding a quantity of an inorganic salt that is not the salt of a weak acid sufficient to adjust the osmolarity to a predetermined level;
- and,
- mixing until said inorganic salt is dissolved;
- and,
- if the concentration of said aqueous solution is greater than a predetermined level, adding additional water;
- further wherein:
- said method does not include any step comprising preparing a solution of any substance therapeutically effective against dry eye syndrome other than HA or PVP;
- and,
- said method does not include any step comprising adding any substance therapeutically effective against dry eye syndrome other than HA or PVP to said composition.
Dependencies are inferred from the claim text.